Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28850272 | 0.80 | NPSR1 (0.38) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL23609878 | 0.79 | NPSR1 (0.41) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL28470162 | 0.79 | HCAR2 (0.52) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL28850237 | 0.77 | NPSR1 (0.36) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL28086841 | 0.73 | FAAH (0.46) | NPSR1GLO1ALDH1A1MAPTFAAH | |
| SCHEMBL2204826 | 0.73 | ALDH1A1 (0.43) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL1370917 | 0.71 | — | — | |
| SCHEMBL13905392 | 0.70 | — | — | |
| SCHEMBL2927909 | 0.70 | — | — | |
| SCHEMBL18512590 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| WO-2025242566-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE CNS | Samsara Therapeutics Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025242565-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF IN THE PREVENTION OR THERAPY OF DISEASES | Samsara Therapeutics Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4653432-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF IN THE PREVENTION OR THERAPY OF DISEASES | Samsara Therapeutics Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4653430-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE CNS | Samsara Therapeutics Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4613745-A2 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | Gilead Sciences, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12365666-B2 | Process for preparing a Cot inhibitor compound | GILEAD SCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| EP-4126862-B1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-119390681-A | Process for preparing COT inhibitor compounds | 吉利德科学公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-0696283-B1 | 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- AND/OR 10-SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | SEARLE & CO (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0696283-A1 | 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- AND/OR 10-SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | SEARLE & CO (US) | 1996-02-14 | — | — | EP | disclosed |
| US-5395932-A | Analgesics, prostaglandin E2 inhibitors | G. D. SEARLE & CO. (US) | 1995-03-07 | — | — | US | disclosed |
| WO-1994025456-A1 | 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- AND/OR 10-SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1994-11-10 | — | — | WO | disclosed |
| EP-0321186-B1 | 6-(Substituted methylene)penems | BEECHAM GROUP PLC (GB) | 1994-03-02 | — | — | EP | disclosed |
| EP-0321187-B1 | 6-(SUBSTITUTED METHYLENE)PENEMS | BEECHAM GROUP PLC (GB) | 1993-07-28 | — | — | EP | disclosed |
| US-4931434-A | Penem compounds | BEECHAM GROUP P.L.C. (GB) | 1990-06-05 | — | — | US | disclosed |
| US-4923856-A | Penem compounds | BEECHAM GROUP P.L.C. (GB) | 1990-05-08 | — | — | US | disclosed |
| EP-0321187-A1 | 6-(Substituted methylene)penems | BEECHAM GROUP PLC (GB) | 1989-06-21 | — | — | EP | disclosed |
| EP-0321186-A1 | 6-(Substituted methylene)penems | BEECHAM GROUP PLC (GB) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | NPSR1 2875/4885GLO1 3438/4885ALDH1A1 2667/4885 |
| US-12365666-B2 | Process for preparing a Cot inhibitor compound | TPO, TFPI, TFPI2 | NPSR1 4695/4885GLO1 1926/4885ALDH1A1 1859/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | NPSR1 3198/4885GLO1 2979/4885ALDH1A1 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.